Literature DB >> 15812265

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

Masaki Kato1, Yuka Ikenaga, Masataka Wakeno, Gaku Okugawa, Kenji Nobuhara, Tsuyoshi Fukuda, Kazuhiro Fukuda, Junichi Azuma, Toshihiko Kinoshita.   

Abstract

The present study aimed to compare the effects of two currently used selective serotonin reuptake inhibitors (SSRIs) in Japan taking the individual background in 5-HTT gene-linked polymorphic region (5HTTLPR) genotype into account. Clinical responses to paroxetine and fluvoxamine were evaluated by total and cluster depressive symptoms for 81 Japanese patients who were diagnosed with major depression. Patients with the l allele had a greater percentage reduction on the total score (P=0.059) and somatic anxiety items (P=0.026) of the 21-item Hamilton Depression Rating Scale (HAM-D) score compared to s/s genotype carriers. Paroxetine was significantly more effective than fluvoxamine in the s/s carriers, as evaluated on the percentage reduction in total score (P=0.012) and core (P=0.049) HAM-D after 4 weeks of medication, but not in the l/s carriers. These findings suggest that the genetic test may be useful in investigating the efficacy of the two SSRIs, and that normalization by the 5HTTLPR genotypes may lead to improvement of the precision of comparative analysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15812265     DOI: 10.1097/00004850-200505000-00005

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  14 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 2.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

3.  The impact of serotonin transporter (5-HTTLPR) genotype on the development of resting-state functional connectivity in children and adolescents: a preliminary report.

Authors:  Jillian Lee Wiggins; Jirair K Bedoyan; Scott J Peltier; Samantha Ashinoff; Melisa Carrasco; Shih-Jen Weng; Robert C Welsh; Donna M Martin; Christopher S Monk
Journal:  Neuroimage       Date:  2011-10-18       Impact factor: 6.556

Review 4.  Fluvoxamine versus other anti-depressive agents for depression.

Authors:  Ichiro M Omori; Norio Watanabe; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Hugh McGuire; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

Review 5.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

6.  Clinical implications of genetic variation in the serotonin transporter promoter region: a review.

Authors:  Nicole S Luddington; Anitha Mandadapu; Margaret Husk; Rif S El-Mallakh
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

7.  Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.

Authors:  Francis E Lotrich; Bruce G Pollock; Margaret Kirshner; Robert F Ferrell; Charles F Reynolds Iii
Journal:  J Psychiatry Neurosci       Date:  2008-03       Impact factor: 6.186

8.  Age-related effect of serotonin transporter genotype on amygdala and prefrontal cortex function in adolescence.

Authors:  Jillian Lee Wiggins; Jirair K Bedoyan; Melisa Carrasco; Johnna R Swartz; Donna M Martin; Christopher S Monk
Journal:  Hum Brain Mapp       Date:  2012-11-05       Impact factor: 5.038

Review 9.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 10.  Personalized medicine in psychiatry: problems and promises.

Authors:  Uzoezi Ozomaro; Claes Wahlestedt; Charles B Nemeroff
Journal:  BMC Med       Date:  2013-05-16       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.